---
title: "BioCryst to Report Second Quarter 2026 Financial Results on August 5"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293471844.md"
description: "BioCryst Pharmaceuticals, headquartered in Research Triangle Park, North Carolina, revealed plans to disclose its financial performance for the second quarter of 2026 on August 5, 2026. The company, listed on Nasdaq as BCRX, made this announcement on July 22, 2026. This upcoming report will provide insights into the company's financial health and performance during the mentioned period. Investors and stakeholders eagerly anticipate this information to assess BioCryst Pharmaceuticals' progress and future prospects."
datetime: "2026-07-22T11:58:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293471844.md)
  - [en](https://longbridge.com/en/news/293471844.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293471844.md)
---

# BioCryst to Report Second Quarter 2026 Financial Results on August 5

BioCryst Pharmaceuticals, headquartered in Research Triangle Park, North Carolina, revealed plans to disclose its financial performance for the second quarter of 2026 on August 5, 2026. The company, listed on Nasdaq as BCRX, made this announcement on July 22, 2026. This upcoming report will provide insights into the company's financial health and performance during the mentioned period. Investors and stakeholders eagerly anticipate this information to assess BioCryst Pharmaceuticals' progress and future prospects.

### Related Stocks

- [BCRX.US](https://longbridge.com/en/quote/BCRX.US.md)

## Related News & Research

- [BioCryst Pharmaceuticals (BCRX) Expected to Announce Quarterly Earnings on Wednesday](https://longbridge.com/en/news/294186102.md)
- [BioCryst Q2 FY26 net income rises to USD 78.4 million; revenue climbs 34% to USD 218.3 million](https://longbridge.com/en/news/294955954.md)
- [BioCryst amends 8-K, estimates $6.2 million-$7.5 million in one-time severance costs for discovery shutdown plan](https://longbridge.com/en/news/294811169.md)
- [BioCryst Q2 2026 earnings: Licensing revenue lifts operating profit](https://longbridge.com/en/news/294961353.md)
- [Supernus Q2 FY26 net loss widens to $58.4 million; revenue rises 32% to $219.1 million](https://longbridge.com/en/news/294679432.md)